Telesis Bio, Inc. (TBIO) |
| 0.051 -0 (-0%) 04-10 09:30 |
| Open: | 0.051 |
| High: | 0.051 |
| Low: | 0.051 |
| Volume: | 574 |
| Market Cap: | 4(M) |
| PE Ratio: | 0 |
| Exchange: | Other OTC |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 1.55 |
| 52w Low: | 0.001 |
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Sun, 12 Apr 2026
Net current asset value per share of Telesis Bio, Inc. – OTC:TBIO - TradingView — Track All Markets
Mon, 09 Jun 2025
Telesis Bio Inks Regeneron Deal - San Diego Business Journal
Wed, 28 May 2025
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis - BioSpace
Thu, 24 Apr 2025
TBIO Stock Price, News & Analysis - Stock Titan
Thu, 10 Apr 2025
Telesis Bio Bullish on Future After Whirlwind Year - San Diego Business Journal
Tue, 18 Mar 2025
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis - Business Wire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |